Dendritic Nanotechnologies gets US contract for ovarian cancer diagnostic and drug delivery:
This article was originally published in Clinica
Executive Summary
Dendritic Nanotechnologies (DNT) has teamed with the US National Cancer Institute (NCI) to develop diagnostic and therapeutic delivery systems for ovarian cancer using its dendrimer nanostructures know-how. The partners have entered into an $850,000 small business innovation research contract, whereby DNT's Priostar dendrimer delivery system will be combined with a magnetic resonance imaging agent to create an improved product for detecting and monitoring cancerous tissue. A second product will combine the Priostar dendrimer with approved cancer-fighting drugs to improve and deliver therapy for ovarian epithelial cancer. Mount Pleasant, Michigan-based DNT expects the project to result in the filing of investigational new drug (IND) applications for the diagnostic imaging technology and for the therapeutic technology. Dendrimers are a type of precisely-defined, branched nanostructure.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.